<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7472261\results\search\disease\results.xml">
  <result pre="of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted" exact="Susceptibility to" post="INSTIs https://orcid.org/0000-0002-7116-0138KirichenkoAlina1*https://orcid.org/0000-0002-6328-1415LapovokIlya1BaryshevPavel1van de VijverDavid A. M. C.2van KampenJeroen J."/>
  <result pre="the features of HIV-1 subtypes for an improved understanding of" exact="viral" post="genetic variability in the occurrence of drug resistance (DR)."/>
  <result pre="we have described the prevalence of INSTI DR in a" exact="Russian" post="cohort and the genetic features of HIV-1 integrase sub-subtype"/>
  <result pre="than 1 million individuals were living with HIV-1 in the" exact="Russian" post="Federation at the end of 2019, which is 0.7%"/>
  <result pre="at the end of 2019, which is 0.7% of the" exact="total" post="population of the country [1]. Advances in combination antiretroviral"/>
  <result pre="the favored class recommended by different international guidelines, including the" exact="Russian" post="treatment guidelines since 2017, as part of first-line treatment"/>
  <result pre="As the name suggests, INSTIs inhibit the second step of" exact="viral" post="replication catalyzed by integrase, i.e., strand transfer, through competitive"/>
  <result pre="RAL and DTG have been included in the Vital and" exact="Essential" post="Drugs guidelines and have been entered as the preferred"/>
  <result pre="Interestingly, these patients were all from Russia and had an" exact="HIV infection" post="with subtype A and the L74I mutation before the"/>
  <result pre="these patients were all from Russia and had an HIV" exact="infection" post="with subtype A and the L74I mutation before the"/>
  <result pre="2 treatment experience participants with the L74I mutation from the" exact="Russian" post="Federation with virological failure after therapy containing CAB [16]."/>
  <result pre="H/K/R) and other accessory mutations (V75I, T97A) can significantly reduce" exact="susceptibility to" post="INSTI, whereas this mutation alone has minimal impact on"/>
  <result pre="integrase gene, are sparse and not well investigated for this" exact="viral" post="clade [18,19,20,21]. Therefore, the expanded use of INSTIs in"/>
  <result pre="study was approved by the Ethics Review Committee of the" exact="Central" post="Research Institute of Epidemiology (Moscow, Russia). 2.2. RNA Extraction"/>
  <result pre="subtypes were determined using integrase sequences by the Stanford HIV" exact="Resistance" post="Database (https://hivdb.stanford.edu/) and subsequently clarified by phylogenetic analysis. 2.4."/>
  <result pre="(https://hivdb.stanford.edu/) and subsequently clarified by phylogenetic analysis. 2.4. HIV-1 INSTI" exact="Resistance" post="Profile Genotyping The Stanford HIV Resistance Database (HIVdb Program"/>
  <result pre="analysis. 2.4. HIV-1 INSTI Resistance Profile Genotyping The Stanford HIV" exact="Resistance" post="Database (HIVdb Program v 8.9-1 and Calibrated Population Resistance"/>
  <result pre="HIV Resistance Database (HIVdb Program v 8.9-1 and Calibrated Population" exact="Resistance" post="Tool) was used to describe and interpret the INSTI"/>
  <result pre="in BEAST v2.2 [48]. We analyzed sequences found within the" exact="Russian" post="samples by using the GTR as the nucleotide substitution"/>
  <result pre="tree was built, and the distribution was assessed from the" exact="posterior" post="tree using TreeAnnotator v1.8 23. 2.8. GenBank Accession Numbers"/>
  <result pre="most frequent clade was sub-subtype A6 (350 sequences; 85.8%). The" exact="viral" post="genetic distribution of other sequences was B (29; 7.1%),"/>
  <result pre="and unusual mutation in DR-position S147T, which does not reduce" exact="susceptibility to" post="any INSTI. Additionally, 3 INSTI-naÃ¯ve patients had accessory mutations:"/>
  <result pre="least one polymorphism was detected within integrase (Figure 1). A" exact="total" post="of 108 mutations were determined in these polymorphic positions."/>
  <result pre="the wild type. It has been reported that in the" exact="absence of" post="major mutations, all these polymorphic mutations had little, if"/>
  <result pre="any, effect on drug susceptibility in vitro, thus suggesting a" exact="secondary" post="role for viral fitness rescue and increasing resistance. The"/>
  <result pre="drug susceptibility in vitro, thus suggesting a secondary role for" exact="viral" post="fitness rescue and increasing resistance. The 9 amino acid"/>
  <result pre="(95% HPD: 1989â€&quot;2003). tMRCA is considered the approximate time of" exact="infection" post="of the potential founder of the sub-subtype A6 epidemic,"/>
  <result pre="epidemics in the world [39,40,41,42]. As expected, the most frequent" exact="viral" post="genetic variant for our data samples was sub-subtype A6"/>
  <result pre="risk group (intravenous drug users), which is typical for the" exact="Russian" post="epidemic since 2015. Because the use of INSTIs was"/>
  <result pre="the features of HIV subtypes for an improved understanding of" exact="viral" post="subtype variability in the occurrence of DR [13,15,16,22,32,33,34,35,36,37,38]. Subtype-specific"/>
  <result pre="[13,15,16,22,32,33,34,35,36,37,38]. Subtype-specific differences related to polymorphic mutations that can affect" exact="viral" post="fitness and can influence INSTI efficacy, even in the"/>
  <result pre="viral fitness and can influence INSTI efficacy, even in the" exact="absence of" post="major DRMs, can be emerging threats to the success"/>
  <result pre="understanding of the prevalence of natural polymorphisms in A6 sub-subtype" exact="infections" post="[18,19,20,21]. Overall, 26.1% of positions in integrase were defined"/>
  <result pre="26.1% of positions in integrase were defined as polymorphic. A" exact="total" post="of 108 mutations were detected, including 16 highly polymorphic"/>
  <result pre="as A1, these gene features allow us to clarify the" exact="viral" post="sub-subtype in samples and correct the data about the"/>
  <result pre="at positions 140 and 151, and subtype B had a" exact="lower" post="genetic barrier to the occurrence of mutations G140C and"/>
  <result pre="in INSTI resistance. Additionally, for position 74, we showed a" exact="lower" post="genetic barrier for L74M and L74I mutations in sub-subtype"/>
  <result pre="that important differences at position 74 may lead to a" exact="lower" post="genetic barrier for the drug resistance pathway in the"/>
  <result pre="of this article show the important role of features of" exact="viral" post="genotypes in drug resistance and also indicate that there"/>
  <result pre="pressure of INSTIs may have clinical and virological implications. A" exact="lower" post="genetic barrier for L74I mutations in sub-subtype A6 can"/>
  <result pre="prevalence of integrase highly polymorphic mutations in A1 and A6" exact="viral" post="clades in treatment-naÃ¯ve patients, Table S3: The prevalence of"/>
  <result pre="of the manuscript. Funding This research was funded by the" exact="Russian" post="Science Foundation (project No. 18-75-10096). Conflicts of Interest The"/>
  <result pre="to publish the results. References References 1.collab: Reference on HIV" exact="Infection" post="in the Russian FederationFederal Scientific for the Prevention and"/>
  <result pre="results. References References 1.collab: Reference on HIV Infection in the" exact="Russian" post="FederationFederal Scientific for the Prevention and Combat of AIDS"/>
  <result pre="Infection in the Russian FederationFederal Scientific for the Prevention and" exact="Combat" post="of AIDS of the Public Office of the Central"/>
  <result pre="and Combat of AIDS of the Public Office of the" exact="Central" post="Scientific Research Institute RospotrebnadzorAvailable online: http://www.hivrussia.ru/(accessed on 31 October"/>
  <result pre="Med.201719778010.1111/hiv.1255929076235 5.SaagM.S.BensonC.A.GandhiR.T.HoyJ.F.LandovitzR.J.MugaveroM.J.SaxP.E.SmithD.ThompsonM.A.BuchbinderS.et al.Antiretroviral Drugs for Treatment and Prevention of HIV" exact="Infection" post="in AdultsJAMA201832037939610.1001/jama.2018.843130043070 6.PokrovskyV.YurinO.KravchenkoA.BelyaevaV.ErmakT.KanestriV.ShahgildyanV.KozyrinaN.BuravtsovaV.NarsiyaR.et al.National recommendations for dispensary observation and"/>
  <result pre="for dispensary observation and treatment of HIV patients. Epidemiology and" exact="Infectious" post="DiseasesTop. Issue20184184 7.AnstettK.BrennerB.G.MesplÃ¨deT.WainbergM.A.HIV drug resistance against strand transfer integrase"/>
  <result pre="2019, Abstract MOPEB257Available online: https://www.hivandmore.de/kongresse/ias2019/002185-Cabotegravir-IAS-2019-Week-48-Pooled-Analysis-from-ATLAS-and-FLAIR-studies.pdf(accessed on 6 July 2020) 17.INSTI" exact="Resistance" post="NotesAvailable online: hivdb.stanford.edu/s/instinotes(accessed on 4 February 2019) 18.LapovokV.L.I.LagaV.KazennovaE.BobkovaM.HIV Type"/>
  <result pre="17.INSTI Resistance NotesAvailable online: hivdb.stanford.edu/s/instinotes(accessed on 4 February 2019) 18.LapovokV.L.I.LagaV.KazennovaE.BobkovaM.HIV" exact="Type 1" post="Integrase Natural Polymorphisms in Viral Variants Circulating in FSU"/>
  <result pre="4 February 2019) 18.LapovokV.L.I.LagaV.KazennovaE.BobkovaM.HIV Type 1 Integrase Natural Polymorphisms in" exact="Viral" post="Variants Circulating in FSU CountriesCurr. HIV Res.20171531832610.2174/1570162X1566617081516205228814231 19.GashnikovaN.M.TotmeninA.V.IvlevV.V.ZyryanovaD.P.AstahovaE.M.GashnikovaM.P.IsmailovaT.N.ChernovA.S.MikheevV.N.Investigation of"/>
  <result pre="Integrase L74F and V75I Mutations in a Clinical Isolate on" exact="Resistance" post="to Second-Generation Integrase Strand Transfer InhibitorsAntimicrob. Agents Chemother.201761e00315-1710.1128/AAC.00315-1728533248 24.OliveiraM.IbanescuR.-I.AnstettK.MÃ©splÃ¨deT.RoutyJ.-P.RobbinsM.BrennerB.G.Selective"/>
  <result pre="regimen by ultra-deep sequencingJ. Antimicrob. Chemother.2018732485249210.1093/jac/dky19829873733 26.LowA.PradaN.TopperM.VaidaF.CastorD.MohriH.HazudaD.MuesingM.MarkowitzM.Natural Polymorphisms of Human" exact="Immunodeficiency" post="Virus Type 1 Integrase and Inherent Susceptibilities to a"/>
  <result pre="ultra-deep sequencingJ. Antimicrob. Chemother.2018732485249210.1093/jac/dky19829873733 26.LowA.PradaN.TopperM.VaidaF.CastorD.MohriH.HazudaD.MuesingM.MarkowitzM.Natural Polymorphisms of Human Immunodeficiency Virus" exact="Type 1" post="Integrase and Inherent Susceptibilities to a Panel of Integrase"/>
  <result pre="and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV" exact="Type 1" post="Infection: 24-Week Results of the VIKING StudyJ. Infect. Dis.201220774074810.1093/infdis/jis75023225901"/>
  <result pre="Evolutionary Model-Based Approach to Quantify the Genetic Barrier to Drug" exact="Resistance" post="in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes"/>
  <result pre="de VijverD.A.WensingA.M.AngaranoG.Ã…sjÃ¶B.BalottaC.BoeriE.CamachoR.ChaixM.-L.CostagliolaD.de LucaA.et al.The Calculated Genetic Barrier for Antiretroviral Drug" exact="Resistance" post="Substitutions Is Largely Similar for Different HIV-1 SubtypesJAIDS J."/>
  <result pre="HIV type-1 B and CRF02_AG subtypesAntivir. Ther.20091412312919320246 34.HillK.J.RogersL.C.NjendaD.T.BurkeD.H.SarafianosS.G.SÃ¶nnerborgA.NeogiU.SinghK.Strain-specific effect on" exact="biphasic" post="DNA binding by HIV-1 integraseAIDS20193358859210.1097/QAD.000000000000207830475264 35.NouhinJ.DonchaiT.HoangK.T.H.KenS.KamkornJ.TranT.AyoubaA.PeetersM.ChaixM.-L.TruongL.X.et al.Natural polymorphisms of"/>
  <result pre="Where do polymorphisms fit in?Futur. Microbiol.2013830330610.2217/fmb.13.10 38.GarridoC.GerettiA.M.ZahoneroN.BoothC.StrangA.SorianoV.de MendozaC.Integrase variability and" exact="susceptibility to" post="HIV integrase inhibitors: Impact of subtypes, antiretroviral experience and"/>
  <result pre="transfer inhibitors cabotegravir and bictegravir in HIV-1 non-B subtypesAIDS20173246947610.1097/QAD.000000000000172629239896 41.FoleyB.LeitnerT.ParaskevisD.PeetersM.Primate" exact="immunodeficiency" post="virus classification and nomenclature: ReviewInfect. Genet. Evol.20164615015810.1016/j.meegid.2016.10.01827789390 42.BobkovaM.Current status"/>
  <result pre="and drug resistance monitoring in the former USSRAids Rev.20131520412 43.LebedevA.LebedevaN.MoskaleychikF.ProninA.KazennovaE.BobkovaM.R.Human" exact="Immunodeficiency" post="Virus-1 Diversity in the Moscow Region, Russia: Phylodynamics of"/>
  <result pre="molecular evolutionThe Phylogenetic Handbook, A Practical Approach to DNA and" exact="Protein" post="Phylogeny3rd ed.LemeyP.SalemiM.VandammeA.M.Cambridge University PressCambridge, UK2012330 45.BishopK.N.HolmesR.K.SheehyA.M.MalimM.H.APOBEC-Mediated Editing of Viral"/>
  <result pre="and Protein Phylogeny3rd ed.LemeyP.SalemiM.VandammeA.M.Cambridge University PressCambridge, UK2012330 45.BishopK.N.HolmesR.K.SheehyA.M.MalimM.H.APOBEC-Mediated Editing of" exact="Viral" post="RNAScience200430564510.1126/science.110065815286366 46.StamatakisA.RAxML version 8: A tool for phylogenetic analysis"/>
  <result pre="drug resistanceJ. Antimicrob. Chemother.201910.1093/jac/dkz41731617907 50.GoethalsO.ClaytonR.van GinderenM.VereyckenI.WagemansE.GeluykensP.DockxK.StrijbosR.SmitsV.VosA.et al.Resistance Mutations in Human" exact="Immunodeficiency" post="Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced"/>
  <result pre="Antimicrob. Chemother.201910.1093/jac/dkz41731617907 50.GoethalsO.ClaytonR.van GinderenM.VereyckenI.WagemansE.GeluykensP.DockxK.StrijbosR.SmitsV.VosA.et al.Resistance Mutations in Human Immunodeficiency Virus" exact="Type 1" post="Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a"/>
  <result pre="Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer" exact="Reduced" post="Susceptibility to a Wide Range of Integrase InhibitorsJ. Virol.200882103661037410.1128/JVI.00470-0818715920"/>
  <result pre="Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced" exact="Susceptibility to" post="a Wide Range of Integrase InhibitorsJ. Virol.200882103661037410.1128/JVI.00470-0818715920 51.CapelE.PareraM.ClotetB.MartÃ­nezM.-A.Significant changes"/>
  <result pre="inhibitorsJ. Antimicrob. Chemother.2010652305231810.1093/jac/dkq32620817922 54.AcharyaA.TagnyC.T.MbanyaD.FonsahJ.Y.NchindapE.KenmogneL.MaJ.NjamnshiA.KanmogneG.D.Variability in HIV-1 Integrase Gene and 3â€²-Polypurine" exact="Tract" post="Sequences in Cameroon Clinical Isolates, and Implications for Integrase"/>
  <result pre="Prevalence of integrase highly polymorphic mutations in A1 and A6" exact="viral" post="clades from treatment-naÃ¯ve patients. The statistically significant differences (p"/>
 </snippets>
</snippetsTree>
